Elsevier

Clinical Therapeutics

Volume 23, Issue 7, July 2001, Pages 1061-1079
Clinical Therapeutics

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis

https://doi.org/10.1016/S0149-2918(01)80092-8Get rights and content

Abstract

Background: Results of phase III clinical trials of rofecoxib, a selective inhibitor of cyclooxygenase 2, have shown that osteoarthritis patients treated with rofecoxib had significantly fewer clinically significant gastrointestinal (GI) adverse events than those who received nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).

Objective: This paper explores the potential economic implications of the use of rofecoxib versus nonselective NSAIDs for the treatment of osteoarthritis via a decision analytic model based on rofecoxib clinical data and the published literature.

Methods: Base-case 1-year analyses were done with data on GI adverse events, specifically perforations, ulcers, and bleeds (PUBs), obtained from a prespecified pooled analysis of the rofecoxib clinical trials. Analyses were also performed using pooled results of two 12-week endoscopic surveillance trials, with adjustments for silent ulcers of 40% and 85%.

Results: Under base-case conditions, the expected cost savings in GI problems and comedications averted with rofecoxib versus NSAIDs was $0.81 per day, representing an 85% offset of the difference in drug price. For rofecoxib versus NSAIDs, the expected cost per PUB avoided with rofecoxib was $4738, and expected cost per year of life saved was $18,614. In analyses based on endoscopic data, therapy with rofecoxib was less expensive than therapy with NSAIDs, regardless of silent ulcer adjustment. Results were most sensitive to prophylactic GI comedication rates, and were robust over a range of model assumptions and costs.

Conclusions: In this analysis based on differences in clinically significant GI events for osteoarthritis patients, cost differences between rofecoxib and NSAIDs were markedly offset by expected cost savings in GI problems and comedications averted with rofecoxib. Costs per year of life saved with rofecoxib versus NSAIDs were well within accepted benchmarks for cost-effectiveness. When endoscopic data alone were considered, rofecoxib was cost savings across all assumptions about silent ulcer rates.

References (64)

  • S Hernandez-Diaz et al.

    Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s

    Arch Intern Med

    (2000)
  • D Henry et al.

    Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis

    Br Med J

    (1996)
  • RC Lawrence et al.

    Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States

    Arthritis Rheum

    (1998)
  • MC Hochberg et al.

    Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology

    Arthritis Rheum

    (1995)
  • MC Hochberg et al.

    Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology

    Arthritis Rheum

    (1995)
  • JA Mitchell et al.

    Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

    Proc Natl Acad Sci U S A

    (1993)
  • B Cryer

    Nonsteroidal anti-inflammatory drugs and gastrointestinal disease

  • LJ Scott et al.

    Rofecoxib

    Drugs

    (1999)
  • MJ Langman et al.

    Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

    JAMA

    (1999)
  • DJ Watson et al.

    Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs)

    Arthritis Rheum

    (1999)
  • D Pettit et al.

    Overview of the Arthritis Cost Consequence Evaluation System (ACCES): A pharmacoeconomic model for celecoxib

    Pharmacoeconomics

    (2000)
  • RA Moore et al.

    Health economic comparison of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom

    J Med Econ

    (2001)
  • TA Burke et al.

    A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis

    Pharmacoeconomics

    (2001)
  • RA Zabinski et al.

    An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada

    Pharmacoeconomics

    (2001)
  • JV Chancellor et al.

    Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor in Switzerland

    Pharmacoeconomics

    (2001)
  • MC Weinstein et al.
    (1980)
  • R Day et al.

    A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis

    Arch Intern Med

    (2000)
  • G Cannon et al.

    Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium

    Arthritis Rheum

    (2000)
  • A Maetzel et al.

    The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

    Arthritis Rheum

    (1998)
  • SE Gabriel et al.

    The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events

    Arthritis Rheum

    (1993)
  • CJ McCabe et al.

    Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK

    Pharmacoeconomics

    (1998)
  • G de Pouvourville

    The economic consequences of NSAID-induced gastropathy: The French context

    Scand J Rheumatol Suppl

    (1992)
  • Cited by (42)

    • Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients

      2005, Joint Bone Spine
      Citation Excerpt :

      This study investigated the use of NSAIDs, one of the most widely prescribed medication classes in the world. Side effects of NSAIDs cause a huge economic burden related to both the cost of treatment and 2 days of work lost [25,26]. Our study suggests that the universal health insurance database in France is a good epidemiological tool for studying prescriptions of medications, medication combinations, and patient profiles.

    • Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: A managed care claims analysis

      2004, American Journal of Medicine
      Citation Excerpt :

      Importantly, while gastroprotection was prescribed in only 2% to 5% of incident NSAID users, use of gastroprotective agents was nearly 61% lower in users of COX-2 inhibitor than in users of traditional NSAIDs. This issue is of particular importance since the cost-effectiveness of COX-2 inhibitors may depend in large part on the rate of coprescription of gastroprotective agents (17,29,30). However, it is difficult to compare this study with ours because the former included only patients older than 65 years and Canadian patients are subjected to more restrictive formulary management.

    View all citing articles on Scopus

    Portions of this research were presented at the 23rd Annual Meeting of the Society of General Internal Medicine, Boston, Massachusetts, May 4–6, 2000.

    View full text